Nicole Petrykowski, DNP, FNP-C, OCN , focuses on desmoid tumor treatment and management, emphasizing shared decision-making with patients. Initial management often involves observation with scans every 3-6 months. Treatment, using sorafe...
Alexis Spence, PharmD, BCOP, shares how clinic pharmacists play a vital role in the care of sarcoma patients, especially those with rare desmoid tumors. They provide an extra layer of support, reviewing medications for potential interact...
Anne Mailhot, PA-C, discusses how her clinic focuses on managing symptoms, primarily pain and quality of life, rather than solely the size of the desmoid tumor. Treatment begins when symptoms interfere with daily life, and its duration i...
Julie Messina, PA-C, explores desmoid tumors treatments and how they often use agents that can affect fertility. Treatment options include nirogacestat and sorafenib, but data on the effects of tyrosine kinase inhibitors on fertility is ...
Katie Sellers, MPAS, PA-C, discusses a phase II trial presented at the ASH Annual Meeting exploring de-escalated post-transplant cyclophosphamide (PTCy) with ruxolitinib for GVHD prophylaxis in older patients undergoing reduced intensity...
Katie Sellers, MPAS, PA-C, considers a post-hoc analysis focusing on transplant recipients aged ≥70 years in the BMT CTN 1703 trial (Abstract 1042). The study found that even in this older, frailer sub-population, post-transplant cycloph...
Katie Sellers, MPAS, PA-C, reviews findings from the Agave-201 study presented at the ASH Annual Meeting, which evaluated axatilimab, an anti-CSF1R monoclonal antibody, in chronic graft-versus-host disease (Abstract 98). Axatilimab showe...
Brad Lewis, MD, of Machaon Diagnostics, covers an analysis of data from 2 studies in patients with acquired hemophilia A. The objective of the current analysis was to report long-term outcomes of emicizumab prophylaxis compared with trad...
Brad Lewis, MD, of Machaon Diagnostics, highlights a study that built on data from the NeST (Neurologic Sequelae of TTP) study and evaluated whether silent cerebral infarction (SCI) is progressive during immune thrombotic thrombocytopeni...
Brad Lewis, MD, of Machaon Diagnostics, reports on a study that evaluated the safety and efficacy of two doses of VAD044 in adults with moderate to severe hereditary hemorrhagic telangiectasia. Results showed that safety and tolerability...
Viviana Perez, APRN, FNP-C, of Moffitt Cancer Center, discusses the first real-world study (N = 4,019) of momelotinib use in patients with myelofibrosis and anemia in the US community oncology practice setting. The results provide import...
Viviana Perez, APRN, FNP-C, of Moffitt Cancer Cancer, discusses research evaluating how differences in “time toxicity” of the bispecific antibodies (BsAbs) glofitamab and epcoritamab may help guide decision-making for patients with relap...
Viviana Perez, APRN, FNP-C, of Moffitt Cancer Cancer, discusses a multicenter, retrospective study evaluating the safety and efficacy of standard-of-care CD19 CAR T-cell therapy in adults with relapsed/refractory transformed indolent NHL...
Laura Zitella, MS, RN, ACNP-BC, AOCN, of UCSF, reviews data that challenge the role of autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL). The TRIANGLE trial demonstrated superior failure-free and overall survival ...
Laura Zitella, MS, RN, ACNP-BC, AOCN, of USCF, discusses abstracts that highlight the potential role of CD19-directed monoclonal antibodies for relapsed/refractory follicular lymphoma. The first showed a decreased risk of progression, re...
Laura Zitella, MS, RN, ACNP-BC, AOCN, of UCSF, discusses a prospective study of patients with newly diagnosed MM who underwent autologous stem cell transplantation (ASCT) followed by lenalidomide maintenance, to investigate the optimal d...
Lindsey E. Kalhagen, MMS, PA-C, discusses a multinational, cross-sectional, online survey study (N = 155) that expanded on previous findings that 20 participants with myelofibrosis (MF) reported, in a series of elicitation interviews, su...
Lindsey E. Kalhagen, MMS, PA-C, discusses a single-center, retrospective, propensity-score matched study that compared clinical response, progression-free survival (PFS) and overall survival (OS) outcomes, and adverse events in 62 patien...
Lindsey E. Kalhagen, MMS, PA-C, discusses a multicenter, observational, retrospective study involving myelofibrosis patients with splenomegaly or symptoms and anemia who received momelotinib from March 2023 to July 2024. This study inclu...
Gloria Espinosa, PharmD, MAT, BCOP, of Thomas Jefferson University Hospital, comments on the safety data of the FLT3 inhibitor quizartinib in patients with FLT3-ITD–positive acute myeloid leukemia. Infections and cytopenias were observe...
Gloria Espinosa, PharmD, MAT, BCOP, of Thomas Jefferson University Hospital, discusses efficacy and safety data for the first-in-class menin inhibitor, revumenib, in patients with relapsed/refractory KMT2A-rearranged acute leukemia. The ...
Tiffany Richards, PhD, ANP-BC, AOCNP®, of The University of Texas MD Anderson Cancer Center, reviews updated efficacy and safety data for BMS-986393 (CC‑95266), a GPRC5D-targeted autologous chimeric antigen receptor (CAR) T-cell therapy ...
Tiffany Richards, PhD, ANP-BC, AOCNP®, of The University of Texas MD Anderson Cancer Center, examines daratumumab (DARA) plus bortezomib, lenalidomide, and dexamethasone (VRd) vs. VRd alone in patients with newly diagnosed multiple myelo...
Gloria Espinosa, PharmD, MAT, BCOP, of Thomas Jefferson University Hospital, discusses the delayed administration of pegaspargase for adults with acute lymphoblastic leukemia, which led to a lower rate of high-grade hepatotoxicity and su...
Tiffany Richards, PhD, ANP-BC, AOCNP®, of The University of Texas MD Anderson Cancer Center, dives into an analysis of minimal residual disease (MRD) negativity from a phase 1/2 trial in t(11;14)-positive relapsed/refractory multiple mye...
Amber Koehler, MPAS, PA-C, of Mayo Clinic discusses an updated analysis of the CD20xCD3 T-cell engaging bispecific antibody, mosunetuzumab, in patients with relapsed/refractory follicular lymphoma and 2 or more prior lines of therapy. Af...
Amber Koehler, MPAS, PA-C, of Mayo Clinic, summarizes key points from an abstract she presented at the ASH Annual Meeting. This study, which spanned over 18 years, examined how initial management strategy (watch and wait vs. treatment) a...
Amber Koehler, MPAS, PA-C, of Mayo Clinic, reports on the favorable outcomes and better tolerability of nivolumab (N) with doxorubicin, vinblastine, and dacarbazine (AVD) compared with brentuximab vedotin (BV) with AVD in patients with n...
Andrew S. Guinigundo, MSN, RN, CNP, ANP-BC, of Cincinnati Cancer Advisors, discusses a study that aimed to investigate the effect of Medicaid expansion on racial disparities in mortality among patients with gastrointestinal malignancies....
Lisa Kottschade, APRN, MSN, CNP, FAPO, of the Mayo Clinic, discusses the NATALEE study, which evaluated adjuvant ribociclib + estrogen therapy (ET) in patients with stage II or III HR+/HER2− early breast cancer (EBC) at risk for recurren...
Oxana Megherea, PharmD, BCOP, of Penn Medicine, University of Pennsylvania Health System, discusses the MonumenTAL-1 study of talquetamab in relapsed/refractory multiple myeloma. Pivotal phase II talquetamab data showed > 70% ORR in h...
Andrew S. Guinigundo, MSN, RN, CNP, ANP-BC, of Cincinnati Cancer Advisors, discusses the phase III DUO-O trial, which evaluates paclitaxel/carboplatin (PC) followed by maintenance bevacizumab (Arm 1); PC plus bevacizumab plus durvalumab ...
Lisa Kottschade, APRN, MSN, CNP, FAPO, of the Mayo Clinic, discusses the planned final overall survival analysis from the ADAURA trial. This study randomized eligible patients (stage IB, II, or IIIA NSCLC) to osimertinib 80 mg once daily...
Oxana Megherea, PharmD, BCOP, of Penn Medicine, University of Pennsylvania Health System, discusses a subgroup analysis of elderly patients enrolled in the phase III POLARIX study. In POLARIX, polatuzumab vedotin plus rituximab, cyclopho...
Andrew S. Guinigundo, MSN, RN, CNP, ANP-BC, of Cincinnati Cancer Advisors, discusses interim results from the DESTINY-PanTumor02 trial, the first tumor-agnostic global study of fam-trastuzumab deruxtecan-nxki (T-DXd) in a broad range of ...
Oxana Megherea, PharmD, BCOP, of Penn Medicine, University of Pennsylvania Health System, discusses results of a phase III study showing that progression-free survival with ibrutinib plus obinutuzumab plus venetoclax (IVO) is not superio...
Lisa Kottschade, APRN, MSN, CNP, FAPO, of the Mayo Clinic, discusses the use of the mRNA-4157 vaccine in combination with pembrolizumab as adjuvant therapy for resected high-risk melanoma, which prolonged distant metastasis–free survival...
Lindsey M. Lyle, MS, PA-C, of the University of Colorado Anschutz Medical Campus, discusses findings from a long-term follow-up of the combination of eprenetapopt and azacitidine in patients with TP53-mutant myelodysplastic syndromes (MD...
Lindsey M. Lyle, MS, PA-C, of the University of Colorado Anschutz Medical Campus, discusses results from a quality improvement initiative in which health-care professionals in two large hospital systems in the United States identified ch...
Sandra Kurtin, PhD, ANP-C, AOCN, of the University of Arizona Cancer Center, discusses a survey that provided insight into the wide range of advanced practice providers’ chemotherapy prescribing practices throughout the United States and...
Sandra Kurtin, PhD, ANP-C, AOCN, of the University of Arizona Cancer Center, discusses results from a study that showed patients with lymphoma or chronic lymphocytic leukemia who have taken part in a clinical trial generally are more con...
Lindsey M. Lyle, MS, PA-C, of the University of Colorado Anschutz Medical Campus, discusses phase III data from the PRINCE study, which showed that patients with paroxysmal nocturnal hemoglobinuria who were naive to complement-inhibitor ...
Kathryn Tyler Maples, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses data of key importance for advanced practitioners on patients with multiple myeloma who are heavily pretreated and predominantly triple-class ...
Kathryn Tyler Maples, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses findings from the MagnetisMM-1 trial on elranatamab, a humanized bispecific molecule that targets BCMA expressed in multiple myeloma and engag...
Kathryn Tyler Maples, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses phase I/II findings from the MajesTEC-1 trial, which seems to confirm that teclistamab monotherapy induces deep and durable responses in heavi...
Sandra Kurtin, PhD, ANP-C, AOCN, of the University of Arizona Cancer Center, discusses the largest reported analysis to date of patients with aggressive B-cell lymphoma who developed progressive disease after CAR T-cell therapy. This is ...
Erin Grannan, PharmD, BCOP, of The University of Texas MD Anderson Cancer Center, discusses the KEYNOTE-522 trial and new phase III findings of interest to advanced practitioners. In the study, researchers found a generally consistent ev...
Sheeba Cantanelli, MPAS, PA-C, of UT Southwestern Simmons Cancer Center, discusses the final phase III results of KEYNOTE-355, which advanced practitioners need to be aware of. The study showed that pembrolizumab and chemotherapy improve...
Donna Kinzler, DNP, ACNP-BC, AOCNP, of the Allegheny Health Network Cancer Institute, discusses phase III findings from the PALLAS study of interest to advanced practitioners. The trial showed that adding 2 years of palbociclib to ongoin...
Donna Kinzler, DNP, ACNP-BC, AOCNP, of the Allegheny Health Network Cancer Institute, discusses the SOPHIA study, which APs need to be aware for their practice. The phase III trial compared margetuximab-cmkb plus chemotherapy (CTX) vs tr...
Sheeba Cantanelli, MPAS, PA-C, of UT Southwestern Simmons Cancer Center, discusses phase III results of a study which showed that when entinostat, an orally bioavailable HDAC inhibitor, is combined with exemestane, it can improve progres...
Erin Grannan, PharmD, BCOP, of The University of Texas MD Anderson Cancer Center, discusses the phase III DESTINY-Breast03 trial, which compared ado-trastuzumab deruxtecan (T-DXd) with standard-of-care trastuzumab emtansine (T-DM1) in pa...
Sheeba Cantanelli, MPAS, PA-C, of UT Southwestern Simmons Cancer Center, discusses phase III findings that showed metformin, which has been linked to beneficial anticancer effects in some research, did not improve invasive disease–free s...
Donna Kinzler, DNP, ACNP-BC, AOCNP, of the Allegheny Health Network Cancer Institute, discusses a genomic analysis of 733 HER2-positive breast cancers, which identified recurrent pathway alterations associated with anti-HER2 resistance a...
Erin Grannan, PharmD, BCOP, of The University of Texas MD Anderson Cancer Center, discusses the latest updates from the SUMMIT trial that advanced practitioners need to be aware of. Researchers explored the promising combinations of nera...
Alexis C. Geppner, MLS, CTTS, PA-C, of The University of Texas MD Anderson Cancer Center, discusses key data that advanced practitioners need to know about treatment for patients with acute lymphocytic leukemia, the shift away from inten...
Alexis C. Geppner, MLS, CTTS, PA-C, of The University of Texas MD Anderson Cancer Center, discusses important updates that advanced practitioners need to be aware of when treating patients with acute myeloid leukemia, including two key d...
Alexis C. Geppner, MLS, CTTS, PA-C, of The University of Texas MD Anderson Cancer Center, discusses key information for advanced practitioners on the impact of TP53 mutations on prognosis in myelodysplastic syndrome, the implications of ...
Lisa Nodzon, PhD, ARNP, AOCNP, of the H. Lee Moffitt Cancer Center & Research Institute, discusses potential new treatment strategies for patients with myelofibrosis that advanced practitioners should be aware of, including anemia th...
Lisa Nodzon, PhD, ARNP, AOCNP, of the H. Lee Moffitt Cancer Center & Research Institute, discusses an update on treating Richter Syndrome, including information on clonally related vs unrelated variants of the disease; the role of ve...
Lisa Nodzon, PhD, ARNP, AOCNP, of the H. Lee Moffitt Cancer Center & Research Institute, discusses key information for advanced practitioners on the B-cell maturation antigen, a target for multiple myeloma, and CAR T-cell therapy, no...
Kelly Valla, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses updates on CAR T-cell therapy and what advanced practitioners need to be aware of when treating patients with rare lymphomas: how best to sequence thes...
Kelly Valla, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses important data that advanced practitioners need to know about bispecific antibodies in the pipeline such as mosunetuzumab, glofitamab, and epcoritamab ...
Kelly Valla, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses mantle cell lymphoma and what advanced practitioners should know about improving outcomes in relapsed and refractory disease with BTK inhibitors such a...
Beth Faiman, PhD, MSN, APRN-BC, AOCN, FAAN, of the Taussig Cancer Institute, Cleveland Clinic, discusses what advanced practitioners need to know about phase III findings on subcutaneous daratumumab plus pomalidomide and dexamethasone. C...
Sandra Kurtin, PhD, ANP-C, AOCN, of The University of Arizona Cancer Center, discusses the challenges for advanced practitioners treating patients with hematologic malignancies who are at high risk for COVID-19 infection. However, the ...
Sara Tinsley, PhD, APRN, AOCN, of Moffitt Cancer Center, discusses what advanced practitioners need to know about the findings of the MURANO study, which analyzed patients with relapsed or refractory chronic lymphocytic leukemia who had ...
Beth Faiman, PhD, MSN, APRN-BC, AOCN, FAAN, of the Taussig Cancer Institute, Cleveland Clinic, discusses key insights for advanced practitioners from the DREAMM-2 study, which detailed the self-reported experiences of patients with relap...
Sandra Kurtin, PhD, ANP-C, AOCN, of The University of Arizona Cancer Center, discusses what advanced practitioners need to know about a novel prognostic index specific to Burkitt lymphoma. The index can identify patients for whom treatme...
Sara Tinsley, PhD, APRN, AOCN, of Moffitt Cancer Center, discusses early insights for advanced practitioners on the safety, efficacy, and toxicities of the drug regimen known as ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, and...
Beth Faiman, PhD, MSN, APRN-BC, AOCN, FAAN, of the Taussig Cancer Institute, Cleveland Clinic, discusses what advanced practitioners need to understand about maintenance treatments with carfilzomib and lenalidomide, and conversion from m...
Sandra Kurtin, PhD, ANP-C, AOCN, of The University of Arizona Cancer Center, discusses the role advanced practitioners can play in managing the unmet medical needs of patients with primary cold agglutinin disease, many of whom had severe...
Sara Tinsley, PhD, APRN, AOCN, of Moffitt Cancer Center, discusses what advanced practitioners need to understand about the findings on safety and efficacy of pevonedistat plus azacitidine vs azacitidine alone in patients with higher-r...
Allyson Price, MPAS, PA-C, of The University of Texas MD Anderson Cancer Center, discusses gene drug mapping, the future of precision medicine in leukemia, and the need for advanced practitioners to educate this patient population who ma...
Allyson Price, MPAS, PA-C, of The University of Texas MD Anderson Cancer Center, discusses the Keynote lecture on two complex disease states, the vital role advanced practitioners play in managing patients on CAR-T therapies, and explain...
Allyson Price, MPAS, PA-C, of The University of Texas MD Anderson Cancer Center, discusses oral hypomethylating agents for MDS, and the implications for advanced practitioners helping patients adhere to the new regimens and maintain good...
Lisa Nodzon, PhD, ARNP, AOCNP, of Moffitt Cancer Center, discusses agents in phase III studies (both ongoing and planned), how the treatment landscape for myelofibrosis is changing, and what advanced practitioners need to know about mana...
Lisa Nodzon, PhD, ARNP, AOCNP, of Moffitt Cancer Center, discusses new drug combinations to treat multiple myeloma, the challenges of managing relapsed and refractory disease, and the role that advanced practitioners need to play in educ...
Lisa Nodzon, PhD, ARNP, AOCNP, of Moffitt Cancer Center, discusses the progress made in treating chronic lymphocytic leukemia, the clinical implications of undetectable minimal residual disease in blood and bone marrow, and how advanced ...
Kelly Valla, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses what advanced practitioners need to know about integrating brentuximab vedotin and PD-1 blockade earlier in the care of patients with Hodgkin lymphoma,...
Kelly Valla, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses insights for advanced practitioners on the many facets of treating peripheral T-cell lymphoma, including stem cell transplants, single agents vs combin...
Kelly Valla, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses next-generation CAR T cells and what advanced practitioners need to understand about enhanced cytotoxicity and increased persistence of the cells, endo...
Sandra E. Kurtin, PhD, ANP-C, AOCN, of the University of Arizona Cancer Center, discusses data from the ICARIA-MM trial that show adding isatuximab to pomalidomide and dexamethasone improved progression-free survival, overall survival, o...
Amy Pierre, ANP-BC, of Memorial Sloan Kettering Cancer Center, discusses a currently enrolling phase III trial on a new strategy to decrease exposure time to ibrutinib, which has the potential to change the standard of care for patients ...
Amy Pierre, ANP-BC, of Memorial Sloan Kettering Cancer Center, discusses study findings on the decreased use of autologous stem cell transplant in older patients with multiple myeloma, despite the therapy’s significant survival benefit. ...
Sara Tinsley, PhD, APRN, AOCN, of Moffitt Cancer Center, discusses study findings that showed most patients with lower-risk myelodysplastic syndrome treated with luspatercept, a first-in-class erythroid maturation agent, achieved indepen...
Sandra E. Kurtin, PhD, ANP-C, AOCN, of the University of Arizona Cancer Center, discusses the findings of a retrospective study that assessed the use of first-line ibrutinib for chronic lymphocytic leukemia in the United States. Although...
Sara Tinsley, PhD, APRN, AOCN, of Moffitt Cancer Center, discusses data that show rigosertib and azacitidine may provide a potential new first-line treatment for patients with high-risk myelodysplastic syndrome (Abstract 4268).
Sara Tinsley, PhD, APRN, AOCN, of Moffitt Cancer Center, discusses study findings suggesting that BTK inhibitors in naive or previously responsive patients with chronic lymphocytic leukemia and allogeneic hematopoietic stem cell transpla...
Sandra E. Kurtin, PhD, ANP-C, AOCN, of the University of Arizona Cancer Center, discusses phase III findings on oral azacitidine, the first treatment used in the maintenance setting shown to improve both overall and disease-free survival...
Amy Pierre, ANP-BC, of Memorial Sloan Kettering Cancer Center, discusses phase III study findings that suggest the combination of carfilzomib, dexamethasone, and daratumumab represents an efficacious new regimen for patients with relapse...
Lindsey M. Lyle, MS, PA-C, of the University of Colorado Cancer Center, discusses the use of glasdegib in addition to intensive or nonintensive chemotherapy in patients with acute myeloid leukemia (Abstract 2732).
Sandra E. Kurtin, PhDc, ANP-C, AOCN, of the University of Arizona Cancer Center, discusses the dual inhibition of Bruton’s tyrosine kinase and BCL2; with the combination of venetoclax and ibrutinib, this drug combination may have broad t...
Josh D. Epworth, MSN, ARNP, of the University of Washington Medical Center, discusses study findings on maintenance therapy with the oral proteasome inhibitor ixazomib, which significantly prolonged progression-free survival following au...
Sandra E. Kurtin, PhDc, ANP-C, AOCN, of the University of Arizona Cancer Center, discusses phase Ib/II study findings on single-agent ibrutinib in the first-line and relapsed or refractory settings for chronic lymphocytic leukemia/small ...
Lindsey M. Lyle, MS, PA-C, of the University of Colorado Cancer Center, discusses preclinical study findings on synergistic antileukemic activity with a combination of the FLT3 inhibitor quizartinib and the MDM2 inhibitor milademetan in ...
Josh D. Epworth, MSN, ARNP, of the University of Washington Medical Center, discusses study findings on pentarefractory multiple myeloma and the responses to oral selinexor plus low-dose dexamethasone (Abstract 598).
Sandra E. Kurtin, PhDc, ANP-C, AOCN, of the University of Arizona Cancer Center, discusses the first phase III prospective data on the impact of minimal residual disease on the long-term clinical outcomes with venetoclax plus rituximab v...
Lindsey M. Lyle, MS, PA-C, of the University of Colorado Cancer Center, discusses study findings on venetoclax in combination with hypomethylating agents, which induced rapid, deep, and durable responses in patients with acute myeloid le...
Josh D. Epworth, MSN, ARNP, of the University of Washington Medical Center, discusses safety and efficacy data on subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma (Abstract 1995).
